HER2-POSITIVE METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer patients who stopped responding to standard therapy
Disease control OngoingThis phase 2 study tests a new drug called ARX788 in 72 adults with HER2-positive metastatic breast cancer that has spread and is not removable by surgery. Participants must have already been treated with a specific prior therapy (T-DXd) and up to 5 total prior treatments. The ma…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New drug cocktail targets breast cancer brain metastases
Disease control OngoingThis study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. The approach aims to improve…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Nancy Lin, MD • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
New drug combo targets tough breast cancer in 40-Patient trial
Disease control OngoingThis study tests a combination of two drugs, tucatinib and alpelisib, in 40 adults with a specific type of advanced HER2-positive breast cancer that has a PIK3CA gene mutation. The goal is to see if the combo is safe and can slow cancer growth. Participants must have cancer that …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New imaging agent lights up HER2 cancers in early trial
Diagnosis OngoingThis study tests whether a new imaging drug, 89Zr-ss-pertuzumab, is safe for people with HER2-positive breast or other cancers. About 60 participants will receive the drug and then have PET scans to see if it can clearly show tumors. The goal is to improve cancer detection withou…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated May 11, 2026 20:39 UTC
-
Can a simple exercise test predict heart risks in breast cancer patients?
Knowledge-focused OngoingThis study looks at how well a cardiopulmonary exercise test (CPET) can measure oxygen use in women with HER2-positive breast cancer who have mild heart problems from their cancer treatment. The goal is to see if this test can help predict how their heart and lungs will handle co…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 03:13 UTC